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Objectives: Lewy body dementia (LBD) causes more morbidity, disability and earlier 
mortality than Alzheimer's disease. Molecular mechanisms underlying neurodegeneration in 
LBD are poorly understood. We aimed to do a systematic review of all genetic association 
studies that investigated people with LBD for improving our understanding of LBD molecular 
genetics and for facilitating discovery of novel biomarkers and therapeutic targets for LBD. 
Methods: We systematically reviewed five online databases (PROSPERO protocol: 
CRD42018087114) and completed the quality assessment using the Quality of genetic 
association studies tool.  
Results: 8521 articles were screened, and 75 articles were eligible to be included. Genetic 
associations of LBD with APOE, GBA and SNCA variants have been replicated by two or more 
good quality studies. Our meta-analyses confirmed that APOE-ε4 is significantly associated 
with dementia with Lewy bodies (pooled odds ratio (POR)= 2.70; 95%CI 2.37-3.07; p<0.001) 
and Parkinson’s disease dementia (POR=1.60; 95%CI 1.21-2.11; p=0.001). Other reported 
genetic associations that need further replication include variants in A2M, BCHE-K, BCL7C, 
CHRFAM7A, CNTN1, ESR1, GABRB3, MAPT, mtDNA Haplogroup-H, NOS2A, PSEN1, 
SCARB2, TFAM, TREM2, and UCHL1. 
Conclusions: The reported genetic associations and their potential interactions indicate the 
importance of α-synuclein, amyloid, and tau pathology, autophagy lysosomal pathway, 
ubiquitin proteasome system, oxidative stress and mitochondrial dysfunction in LBD. There is 
a need for larger GWAS for identifying more LBD associated genes. Future hypothesis-driven 
studies should aim to replicate reported genetic associations of LBD, and to explore their 
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Key points 
 Genetic associations between DLB and genetic variants in APOE, GBA and SNCA have 
been replicated by at least two good quality studies 
 Genetic associations of PDD with variants in APOE and GBA have been replicated  








 Lewy body dementia (LBD) is the second most common neurodegenerative dementia 
after the dementia in Alzheimer's disease (AD), and it accounts for 15-30% of all 
neurodegenerative dementias1,2. LBD comprises of two overlapping clinical syndromes, 
dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD)2. LBD is 
associated with increased mortality3, earlier nursing home admissions, higher risk of falls, 
poorer quality-of-life, higher costs4 and more caregivers’ burden than AD. Overall, LBD 
carries a poorer prognosis than AD, with accelerated cognitive decline and a greater negative 
impact on quality-of-life5. The search for disease modifying drugs and reliable peripheral 
biomarkers for LBD is still ongoing2.  
 Despite the public health importance of LBD, very little is known about the molecular 
pathology underlying neurodegeneration in LBD. Systematic research on the genetics of LBD 
remains sparse. While most cases of LBD appear sporadic, several studies have reported 
familial aggregation of LBD and its core features such as visual hallucinations and cognitive 
fluctuations6,7. Siblings of probands with DLB have been reported to have significantly higher 
risk of developing DLB than the siblings of probands with AD7. Research in these families has 
supported a role for genes implicated in both AD (APP, PSEN1, PSEN2, PGRN, PRNP) and 
Parkinson’s disease (PD) (SNCA, SNCB, LRRK2, GBA) with the development of DLB and 
PDD8. However, Autosomal dominant inheritance mutations in  SNCA and LRRK2 in people 
with LBD have been reported. PDD has been associated with variants in PARK1, PARK4, GBA, 
MAPT, LRRK2 and APOE9. While the variants in APOE and GBA have been associated with 
both DLB and PDD, the associations are stronger for DLB over PDD10. Most of the candidate 
gene association studies that investigated the genetics of LBD were small and their findings 
were poorly replicated. The first genome-wide association study (GWAS) investigating DLB 





associations between DLB and variants in APOE, SNCA, and GBA11. Further imputation and 
genome-wide complex trait analysis of the GWAS data have updated the heritability of DLB 
as 59.9%, and have indicated that the genetic risk factors for DLB are likely to be independent 
from known AD and PD risk variants12.   
 Identification of genetic variants associated with LBD will improve our understanding 
of neurodegeneration in LBD and its molecular pathogenesis. Identifying a unique genetic 
profile will help in distinguishing LBD from AD and defining the nosological boundaries 
between DLB and PDD. This can facilitate discovery of reliable diagnostic biomarkers for 
LBD and of novel targets for future therapeutic approaches. In order to provide a 
comprehensive summary of all available evidence on the genetic associations of LBD, we 
aimed to conduct the first systematic review of all genetic association studies that investigated 
people with LBD.  
 
Methods 
Study design: The protocol for this systematic review has been registered in the international 
prospective register of systematic reviews (PROSPERO protocol CRD42018087114; available 
at http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018087114). 
Search strategy: We systematically searched the following online databases: 
MEDLINE/PubMed (since 1946), EMBASE (since 1974), PsycINFO (since 1806), CINAHL 
Complete (since 1937), OpenGrey and Bielefeld Academic Search Engine (BASE) (since 
2004). The search strategy included combinations of population search terms and exposure 
search terms. The population search terms were (‘Lewy’ OR ‘Parkinson*’) AND ‘Dementia’. 
The exposure search terms included ((‘Gene*’ AND (‘association*’ OR ‘variant*’ OR 
‘polymorphism*’)) OR (Genome AND association*) OR ‘mutation*’ OR ‘SNP’ OR ‘CNV’ 





searches were limited to 3rd February 2018 and to English. Reference lists of the studies 
included in the review were explored for identifying other potentially eligible studies. 
Eligibility criteria: We included all genetic association studies that satisfied the following 
inclusion criteria, i) they were human studies. Studies on animals or cell lines were not 
included, ii) they presented original research data, iii) participants in at least one study group 
were clinically diagnosed to have DLB or PDD or LBD, iv) there was a control group in which 
LBD was clinically ruled out. The controls were either older people without cognitive 
impairment or those with other neurodegenerative disorders excluding LBD. We excluded 
studies that were not published in English.  
Study selection: We screened for all eligible candidate gene association studies and GWAS 
investigating the genetic associations of LBD. We merged our search results and removed 
duplicates. We excluded the abstracts that did not mention investigating the genetic 
association(s) between LBD and one or more genetic variants. We attempted retrieving full 
texts of all potentially eligible abstracts, and a three member review team assessed the 
eligibility of the full-text papers. When a conference abstract was not accompanied by its full 
presentation, we requested further details from the corresponding author, if the contact 
information was provided. If the corresponding author did not respond to our request within 14 
days, we excluded that abstract.   
Data extraction: We extracted the following data, i) population characteristics including their 
mean age and ethnicity, (ii) sample size in each study group, iii) definition of the phenotype, 
iv) investigated genetic variant(s), v) genotyping method, vi) study findings with effect size 
and p-values, vii) statistical correction for multiple testing, viii) statistical analyses addressing 
the effects of potential confounders.  
Quality assessment: We assessed the quality of eligible studies using the Quality of genetic 





the rationale for study, (ii) selection and definition of outcome, (iii) selection and comparability 
of comparison groups, (iv) technical classification of the genetic variant(s), (v) non-technical 
classification of the genetic variant(s), (vi) other sources of bias, (vii) sample size and power, 
(viii) a priori planning of statistical analyses, (ix) statistical methods and control for 
confounding, (x) tests of assumptions and inferences for the genetic analyses, and (xi) 
appropriate interpretation of the study results.  Each dimension is scored on a scale from one 
(poor) to seven (excellent). For studies with control group, Q-Genie total scores ≤35 indicate 
poor quality, total scores more than 45 indicate good quality, and total scores between 36 and 
45 indicate moderate quality. The reliability and validity of the Q-Genie tool has already been 
demonstrated14. We assessed the interrater reliability of the Q-genie scores between the three 
members of the review team using the STATA 15.1 software (StataCorp LLC, TX, USA). The 
two-way mixed-effects intraclass correlation coefficient (ICC) analyses confirmed moderate 
reliability (ICC=0.70).  
Data reporting: When the studies included in this systematic review have reported the dbSNP 
identifiers (rs IDs) of their investigated genetic variants, we have extracted the information, 
and have reported them in this review. When the included studies have not reported the dbSNP 
identifiers, we searched the dbSNP database (https://www.ncbi.nlm.nih.gov/snp) with the 
reported names of the variants.  When our search could not establish a unique dbSNP identifier, 
we have reported the variant name as it was reported by the original study authors. We report 
the results of included studies using the descriptors ‘positive’ for statistically significant 
associations with p-values less than 0.05 (after multiple testing correction, if available), and 
‘negative’ for the lack of statistically significant (p≥0.05) associations.  
Data synthesis: A descriptive synthesis was carried out using the extracted data and major 
findings of each included study. We have synthesized the data by listing the genetic 





three or more studies investigated the genetic association between a single genetic variant and 
a specific outcome variable, we conducted either fixed or random-effects meta-analyses using 
the STATA 15.1 software (StataCorp LLC, TX, USA) and its “metan” command. Later, we 
grouped these genetic associations by their potential functional links to the complex 
aetiopathogenesis of LBD. We have discussed the potential functional implications of the 
reported genetic associations within the context of available literature.  
 
Results 
 We identified and screened 5125 papers after removing the duplicates and found 75 
papers eligible to be included in this systematic review. Figure-1 presents the study selection 
process in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) format15. Our quality assessment using the Q-Genie rated 31 (41.3%) included 
studies as poor, 27 (36.0%) studies as moderate quality, and 17 (22.7%) studies as good (See 
supplementary table-1). Statistically significant genetic associations have been reported 
between LBD and the genetic variants in A2M, APOE, BCHE, BCL7C, CHRFAM7A, CNTN1, 
ESR1, GABRB3, GBA, MAPT, NOS2, PSEN1, SCARB2, SNCA, TFAM, TREM2, UCHL1, and 
mitochondrial DNA (mtDNA) Haplogroup H. Associations between DLB and variants in 
APOE, GBA, SNC and MAPT and between PDD and variants in APOE and GBA have been 
replicated by two or more studies. There has been only one GWAS investigating DLB that has 
reported genome-wide significant associations between DLB and rs429358 (APOE), 
rs7681440 (SNCA), rs35749011 (GBA), rs897984 (BCL7C/ STX1B), and rs1426210 (GABRB3) 
in its discovery stage11. There has not been any GWAS investigating people with PDD so far. 
APOE: The APOE variants, especially its ε4 allele, are the most studied among all genetic 
variants in people with LBD16-41. Apolipoprotein-E (APOE) is involved in cholesterol 





amyloid aggregation16. Among the 25 studies that investigated the association of APOE-ε4 
with DLB, 21 have demonstrated a statistically significant association between APOE-ε4 and 
DLB (Table-1). The 21 positive studies included six good quality, eight moderate quality and 
seven poor quality studies, and the negative studies included one good, one moderate, and two 
poor quality studies. We conducted a meta-analysis including data from 18 positive studies and 
all four negative studies (Figure-2). We did not include three positive studies, because they did 
not provide allele frequency data. There was significant heterogeneity (χ2=45.18, df=21; 
p=0.002) among the studies, and the random effects meta-analysis confirmed that the APOE-
ε4 is significantly associated with increased risk of DLB (pooled odds ratio (POR)= 2.70; 
95%CI 2.37-3.07; p<0.001). Moreover, statistically significant associations with probable 
reduced risk of DLB22 have been reported between APOE-ε2 and DLB21-23,29. Similarly, one 
of the studies investigating the association between APOE-ε3 and DLB has reported 
statistically significant reduced risk for DLB29. Furthermore, two moderate quality studies32,42, 
and one poor quality study including PD controls without dementia (PDND)43 have reported 
statistically significant associations between APOE-ε4 and PDD. Another moderate quality 
study has reported significantly increased frequency of APOE-ε4 in a LBD group including 
people with DLB and PDD compared to PDND controls44. However, eight studies including 
two good, four moderate, and two poor quality studies did not find statistically significant 
association between APOE-ε4 and PDD19,30,45-50. We conducted a meta-analysis including data 
from the four positive studies and seven negative studies (Figure-3). There was significant 
heterogeneity (χ2=29.22, df=11; p=0.002) among the studies, and the random effects meta-
analysis confirmed that the APOE-ε4 is significantly associated with increased risk of PDD 
(POR=1.60; 95%CI 1.21-2.11; p=0.001). 
GBA: The glucosylceramidase beta gene (GBA) encoding the lysosomal glucosylceramidase 





increase the risk of earlier onset cognitive impairment in PD. Six studies10,11,28,32,41,52 including 
four good quality studies have reported statistically significant associations between DLB and 
GBA variants including rs223028810, rs7676371548, rs36806032,52, rs3574901111, and  
rs42101628 (Table-2).  Moreover, two studies have reported statistically significant associations 
between GBA variants and PDD10,30 (Table-3). 
SNCA: α-synuclein encoding SNCA variants rs97471119, rs134822419 and rs768144011 have 
been associated with DLB. However, studies that investigated SNCA triplication53, SNCA 
variant rs10489387754 and variants in α-synuclein interacting protein encoding SNCAIP55 did 
not find statistically significant associations with DLB. Moreover, SNCA variants rs10018362 
and rs768994219 were significantly increased in PDD, and SNCA variants rs1372525, 
rs2583988, rs2619364, rs2619363 and rs2301135 were not significantly associated with 
PDD56. Apart from the replicated association between DLB and rs768144011, the reported 
genetic association findings between LBD and other SNCA variants have not been replicated 
so far. 
MAPT: MAPT encodes tau protein. Two moderate57,58 and one poor quality59 studies have 
reported significant association between MAPT H1 haplotype and DLB, but two good quality 
studies have not replicated this finding11,37. Moreover, a moderate quality study has reported 
associations between PDD and MAPT H1 haplotype and another probably protective variant 
rs146796760. 
Other genetic associations: Table-2 and Table-3 present other reported genetic associations of 
DLB, and PDD, respectively. The only GWAS has replicated the association between DLB 
and rs7314908 of CNTN111. The reported genetic associations between DLB and rs897984 
(BCL7C)11, 2bp in exon 6 of CHRFAM7A17, rs1426210 (GABRB3)11, mtDNA haplogroup H25, 
SCARB2 variants24 need further replication. Conflicting evidence exist for the genetic 





PSEN126,64, TREM211,28,65. Studies that investigated the genetic associations of DLB with 
variants in A2M66, AACT29, ADORA167, BDNF18, CYP2D668, DBH27, LRRK269, NOS362, 
PARK770, PRGN71, RAB39B72, SNCB73, TFAM74 and TF75 did not find statistically significant 
associations. Moreover, two studies have reported conflicting evidence regarding the genetic 
associations between PDD and variants in ESR176,77. The reported genetic associations between 
PDD and variants in A2M78,  TFAM (rs2306604)74, and UCHL1 (rs4861387)79 have not been 
replicated so far. Studies that investigated the genetic associations of PDD with variants in 
BDNF80, CYP2D681, IL-1082, IL-1882, MMP1283, NAT284, PPARGC1A85, PPARG85, PSEN286, 
RAGE87, SLC6A488, TOMM4044 and TREM289 have reported negative findings. 
 
Discussion 
 This is the first systematic review of all genetic association studies that investigated 
people with LBD. We have summarised all reported genetic associations and have highlighted 
the genetic associations that have been replicated. The strengths of this systematic review 
include its broad inclusion criteria, searching multiple databases including grey literature, 
following PRISMA guidelines, and rigorous quality assessment using the Q-Genie instrument. 
However, we should acknowledge the limitations of excluding studies that were published in 
other languages, not including gene expression and epigenetic studies, and of substantial 
heterogeneity among the included studies. Apart from one exome sequencing study and one 
GWAS, other eligible studies were candidate gene association studies. Most of them were 
small, and they have not reported sample size estimation or power analysis, so they were prone 
to type-II error. They differed widely on their population characteristics, case definitions, 
selection of controls, and statistical analyses. Many studies did not employ appropriate 
statistical corrections for multiple testing, so their findings were prone to type-I error. Most of 





limited generalisability. Furthermore, the second GWAS investigating DLB was published 
after the completion of this systematic review in May 201990. The GWAS confirmed the 
genetic associations of DLB with APOE-ε4 and GBA, and it reported a suggestive association 
between DLB and ZFPM1. Moreover, the first genome-wide analysis of copy number variants 
(CNV) in people with DLB was also published in May 201991. Five CNV regions including 
ADGRG7, TFG, PDZD2, LAPTM4B, MSR1, NME1, NME2, and SPAG9 were reported to have 
genome-wide significant associations with DLB91. 
 APOE-ε4 variant has the largest body of evidence in this topic16-41. Two GWAS have 
confirmed the genome-wide significant association between APOE-ε4 and DLB. Our meta-
analyses have confirmed this association, and the genetic association between APOE-ε4 and 
PDD. Similar to this genetic association, the molecular genetics of LBD has been hypothesised 
to overlap with known genetic associations of AD and PD8. However, the genetic overlap is 
limited to only a few genes including APOE, ESR1, MAPT, PSEN1, TFAM, and TREM2 that 
have been reported to be associated with both LBD and AD92-94. Despite the overlap in genetics 
of LBD, AD and PD, there are substantial variations in their clinical presentation and 
longitudinal progression. These variations may be explained by genetic risk variants specific 
to LBD, gene environment interactions, epigenetics, and various environmental factors. There 
is a need for more systematic studies investigating gene environment interactions in people 
with LBD. A recent genome-wide meta-analysis has identified 29 risk loci for AD93, and only 
two of those genes, APOE and TREM2, have been reported to be associated with LBD so far. 
Notwithstanding the limited power of most of the LBD genetic association studies, several 
genes that have not been associated with AD such as CNTN1, BCL7C, and GABRB3, and 
several genes that have been associated with PD such as GBA, SNCA, UCHL1, and SCARB2 
have been associated with LBD. These genetic associations imply that the molecular pathology 





differences. Further studies are warranted for replicating these genetic associations, and for 
investigating their functional implications, and biomarker potential. Future LBD genetic 
association studies should not limit their focus only on known AD or PD risk genes, and there 
is a need for larger GWAS and transcriptomic studies investigating the molecular genetics of 
LBD. 
LBD is an α-synucleinopathy95, and its reported genetic associations indicate the 
importance of autophagy lysosomal pathway (ALP), ubiquitin proteasome system (UPS), 
oxidative stress and mitochondrial dysfunction in its complex etiopathology. Aggregation of 
α-synuclein leads to the formation of Lewy bodies96, and the genes that are implicated in 
increased α-synuclein aggregation either directly (SNCA, PSEN197) or indirectly (MAPT57-60.) 
have been associated with LBD98. SNCA variants and MAPT H1subhaplotypes have been 
associated with increased tau fibrilization and deposition59,60,99,100. Potential interactions 
between these variants may lead to synergistic neurodegenerative effects of amyloid, tau and 
α-synuclein deposition60,101.  Moreover, PSEN1 variants may contribute to neurodegeneration 
in LBD through increased amyloid deposition97. The L435F PSEN1 minor allele reportedly 
leads to progressive loss of cortical neurons, increased apoptosis, astrogliosis and microgliosis 
in PSEN1 knock-in mice102.  
 The genetic associations between GBA variants and PD are well known, and the people 
with PD carrying GBA variants are at higher risk for developing PDD103,104. However, little is 
known about how GBA variants contribute to neurodegeneration in people with LBD. ALP and 
UPS are important cellular systems responsible for the degradation of misfolded proteins105. 
GBA variants are likely to impair ALP and to cause cytoplasmic accumulation of misfolded 
proteins. Lysosomal dysfunction coupled with higher misfolded protein burden may 
overwhelm the UPS and autophagy pathways, and may increase α-synuclein aggregation51. 





reported to cause α-synuclein aggregation and neurotoxicity in stem cell-derived neurons106. 
Such aggregated α-synuclein may set off a self-propagating disease by inhibiting neuronal 
lysosomal activity106. Moreover, SCARB2 gene encodes a lysosomal membrane protein that 
transports GBA to lysosomes and its deficiency may lead to reduced GBA activity and α-
synuclein accumulation107. Furthermore, UCHL1 is essential for reuse of free ubiquitin and 
hydrolysis of substrates by neuronal UPS, and its loss of function may contribute to the 
formation of Lewy bodies79,108.  
 The mitochondrial cascade hypothesis for AD states that an individual’s mtDNA 
determines baseline mitochondrial function that declines with age and environmental insults 
resulting in AD pathology109. As LBD has been found to be associated with mtDNA 
haplogroup H, independent of APOE genotype25, the similar mitochondrial cascade hypothesis 
can be considered for LBD. APP has been found to be targeted to the mitochondria, and its 
progressive accumulation on mitochondrial membrane may cause mitochondrial 
dysfunction110. TFAM encodes mitochondrial transcription factor A (TFAM) that is essential 
for mitochondrial transcription and mtDNA replication. TFAM variants impairing its function 
may lead to mitochondrial dysfunction and neurodegeneration111. TFAM overexpression has 
been reported to improve hippocampal long-term potentiation and motor learning memory in 
mice106. It has been found to reduce expression of inflammatory mediators such as interleukin-
1β and to reduce mtDNA damage in microglia111. Moreover, mitochondrial dysfunction in 
LBD may lead to a vicious cycle by producing more reactive oxygen species that in turn 
causing more mitochondrial oxidative damage112. Resulting oxidative stress may lead to α-
synuclein aggregation worsening the vicious cycle by impairing more mitochondria112. Further 
studies are warranted for investigating these hypotheses, and the molecular mechanisms 





 A2M, TREM2, CNTN1, NOS2, and ESR1 are implicated in protein degradation and/or 
neuronal survival. A2M encodes an antiprotease that inhibits various proteinases, and it may 
contribute to the formation of Lewy bodies and amyloid plaques113,114. TREM2 variants have 
been associated with early-onset dementia115, and they may impair autophagy and clearance of 
misfolded proteins116. CNTN1 encodes contactin 1 that modulates remyelination and 
neuroinflammation and regulates the activity of APP cleaving enzyme BACE111,117. NOS2 
generates nitric oxide in neurons and microglia, and it promotes cell survival though inhibition 
of apoptosis118. Less NOS2 CCTTT repeats leads to reduced level of nitric acid synthase that 
may increase oxidative stress, and may impair neuronal survival in LBD38. ESR1 encodes 
oestrogen receptor alpha (ERα) that mediates the physiological effects of Estradiol-17-β 
including neuroprotective and antiapoptotic effects, especially survival of cholinergic 
neurons119, modulating APP processing119,120, and maintaining  synaptic density121. It has been 
reported that Estradiol-17-β and ESR1 activation may upregulate APOE-ε4 expression122, and 
there is a need for further studies investigating the functional implications of reported genetic 
associations between ESR1 variants and LBD. Moreover, cholinergic system dysfunction may 
play an important role in LBD pathology. The BCHE-K variant results in nearly 30% less 
Butyrylcholinesterase activity33 and it has been associated with reduced tau phosphorylation in 
people with dementia123. The BCHE-K variant has been found to be significantly less common 
among people with DLB33. Additionally, the reported genetic association between 
CHRFAM7A and LBD may highlight the importance of cholinergic system dysfunction in 
LBD17,124. CHRFAM7A is a duplicated gene complex including CHRNA7 that encodes 
neuronal acetylcholine receptor subunit α-7 (nAChRα7). nAChRα7 has been implicated in the 
pathology of several neuropsychiatric disorders, and it is involved in memory, sensory 





 In comparison to the field of molecular genetics of AD or PD, pertinent research 
investigating genetics of LBD is still at an early stage. The field of LBD genetics has recently 
joined the GWAS era11,90. None of the reported genetic asscoiations warrant routine genetic 
testing in clinical settings at present, and the field is far from translating the knowledge of 
genetics to clinical diagnostic and therapeutic applications. As a definite diagnosis of DLB can 
be confirmed only by post-mortem neuropathological verification1, it is difficult to rule out 
misclassification bias in any candidate gene association study or GWAS investigating people 
living with LBD. However, there is a need for larger GWAS and broader international 
collaborations for identifying more LBD associated genes. The reliability of clinical diagnoses 
of LBD should be pathologically verified by post-mortem examination of brains of a few study 
participants. Then, the field can catch up with the post-GWAS era126 in understanding the 
molecular mechanisms underlying the identified genetic associations. Meanwhile, there is a 
need for more hypothesis-driven studies for replicating reported genetic associations of LBD, 
and for exploring their functional implications. Gene expression studies and transcriptomic 
analyses of post-mortem LBD brains or of circulating exosomes of people living with LBD 
may help understanding the functional significance of the genetic associations, and their 
molecular networks127-130. Future hypothesis-driven studies should prioritize the identified 
genetic associations of LBD that do not overlap with known AD risk genes.  Such studies may 
advance our understanding of molecular mechanisms underlying neurodegeneration in LBD 
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Table 1: The studies that have reported statistically significant genetic association between APOE-ε4 and Dementia with Lewy Bodies.  
 
 
‡: Cases were patients with SDLT (Senile dementia of Lewy body type); §: Odds ratios were calculated using the reported allele 
frequency data; NR: Not reported; NS: not significant.  
 
Study Cases: Controls ε4 allele numbers  
Cases: Controls 
Odds Ratio 
 (95% CI) 
p value 
Harrington et al 199416 ‡26:58 19:17 4.56 (1.53-13.84) p=0.003 
Benjamin et al 199521 ‡28:46 20:14 3.10 (1.41-6.81)§ p=0.004 
Lamb et al 199829 49:101 35:29 3.31 (1.87-5.86)§ p=6.25x10-5 
Chinnery et al 200025 84:179 No frequency data NR p<0.001 (1 ε4 allele) 
p=0.007 (2 ε4 alleles) 
Xu et al 200034 22:101 14:29 2.78 (1.32-5.87)§ p<0.05 
Singleton et al 200231 76:111 50:28 3.50 (2.1-5.9) p=5.6x10-6 
Huckvale et al 200327 53:720 48:202 5.07 (3.36-7.65)§ p<0.001 
Akatsu et al 200420 31:387 12:64 2.66 (1.35-5.26)§ p<0.005 
Borroni et al 200623 82:81 36:19 2.11 (1.15-3.87) p=0.018 
Feher et al 200917 35:175 19:27 4.46 (2.31-8.60)§ p<0.0001 
Feher et al 200918 34:164 19:29 4.00 (2.08-7.68)§ p<0.0001 
Meeus et al 20128 99:626 49:193 1.81 (1.26-2.58)§ p<0.001 
Tsuang et al 201335 91:269 58:39 6.10 (3.5-10.5) p=1.2x10-16 
Berge et al 201422 156:643 100:185 5.90 (2.7-13.0) p≤0.0005 (1  ε4 allele) 
p≤0.0005 (2  ε4 alleles) 
Geiger et al 201626 111:222 No frequency data NR p<0.001 
Guella et al 201619 922:971 620:318 2.50 (2.29-2.70) p<0.002 
Keogh et al 201641 87:93 51:26 2.55 (1.51-4.32)§ p=0.0001 
Vijayaraghavan et al 201633 174:86 108:23 2.92 (1.78-4.78)§ p<0.001 
Keogh et al 201728 55:359 34:107 2.56 (1.62-4.02)§ p<0.001  
Guerreiro et al 2018 (discovery)11  1216:3791 688:1061 2.40 (2.14-2.70) p=1.05x10-48  





Table 2: The studies that have reported other statistically significant genetic associations of Dementia with Lewy Bodies (DLB) 
 
mtDNA: mitochondrial DNA; † higher K allele frequency in controls vs DLB case group; §: Odds ratios (OR) were calculated using 
the reported allele frequency data; NR: Not reported.  
Study  Gene Cases: Controls Variant(s) OR (95% CI) p value 
Vijayaraghavan et al 201633 BCHE 174:86 One or two K alleles 0.49 (0.34-0.71)§ p<0.001† 
Guerreiro et al 201811 BCL7C 1743:4454 rs897984 0.74 (0.67-0.82) p=3.30x10-9 
Feher et al 200917 CHRFAM7A 35:175 2 bp deletion at 497–498 in exon 6 3.76 (2.21-6.39)§ p=0.001 
Guerreiro et al 201811 CNTN1 1743:4454 rs7314908 1.51 (1.27-1.79) p=2.32x10-6 
Guerreiro et al 201811 GABRB3 1743:4454 rs1426210  1.34 (1.21-1.48) p=2.62x10-8 
Nalls et al 201310 GBA 721:1962 “Mutations” 8.28 (4.78-14.88) p=5.52x10-15 
Nalls et al 201310 GBA 721:1962 rs2230288  2.72 (1.38-5.54) p=0.006 
Keogh et al 201641 GBA 87:93 5 GBA variants NR p=0.043 
Mata et al 200852 GBA 57:554 rs76763715 or rs368060 10.00 (1.7-139.8) p=0.045 
Tsuang et al 201232 GBA 79:391 “Pathogenic GBA mutation carriers”  7.60 (1.8-31.9) p=0.001 
Keogh et al 201728 GBA 58:368 rs421016 NR p=0.008 
Guerreiro et al 201811 GBA 1743:4454 rs35749011 2.55 (1.88-3.46) p=1.78x10-9 
Labbe et al 201657 MAPT  431:1049 H1G haplotypes 3.30 (1.34-8.12) p=0.002 
Labbe et al 201657 MAPT 431:1049 H1L haplotypes 0.37 (0.15-0.92) p=0.041 
Labbe et al 201558 MAPT 442:1679 rs143624519 5.76 (1.62-20.51) p=0.007 
Cervera-Carles et al 201659 MAPT 51:325 H1 allele 1.81 (1.05-3.14) p=0.032 
Chinnery et al 200025 mtDNA 84:179 Haplogroup H NR p=0.034 
Xu et al 200034 NOS2 22:101 (CCTTT)n repeat 5.04 (1.5-16.9) p<0.01 
Geiger at al 201626 PSEN1 111:222 rs17125721  2.10 (1.04-3.76) p=0.035 
Guella et al 201619 SNCA 922:971 rs974711 1.22 (1.07-1.38) p<0.002 
Guella et al 201619 SNCA 922:971 rs1348224 0.74 (0.65-0.85) p<0.002 
Bras et al 201424 SNCA 788:2624 Not specified NR p=3.7x10-5 
Guerreiro et al 201811 SNCA 1743:4454 rs7691440 0.73 (0.66-0.81) p=6.39x10-10 
Bras et al 201424 SCARB2 788:2624 Not specified NR P<0.001 





Table 3: The studies that have reported statistically significant genetic associations of Parkinson’s Disease Dementia (PDD) 
Study  Gene Cases: Controls Variant(s) OR (95% CI) p value 
Sleegers et al 200478 A2M  9 (LBD):283 D-allele 0.67 (0.23-1.96)§ p=0.009 
Harhangi et al 200042 APOE 26:4805 ε2, ε3, ε4 2.20 (1.7-2.9) Significant†  
Tsuang et al 201232 APOE 81:269 ε2, ε3, ε4 3.10 (1.7-5.6) p=1.94x10-5 (ε4 allele) 
Arai et al 199443 APOE 14:49 (PDND) ε2, ε3, ε4 4.68 (1.64-13.36)§ p<0.001 
Lindqvist et al 201644 APOE 55 (PDD) + 101 (DLB): 
92 (PDND) 
ε4 2.26 (1.18-4.34) p<0.014 
Isoe-Wada et al 199976 ESR1 13:51 
13:71 (PDND) 
PvuII 2.81 (1.16-6.83)§ 
3.34 (1.41-7.93)§ 
p<0.02 (PDD vs CTL) 
p=0.0073 (PDD vs PDND) 
Nalls et al 201310 GBA 151:1962 “Mutations” 6.48 (2.53-15.37) p=9.66x10-6 
Nalls et al 201310  151:1962 rs2230288  3.91 (1.41-10.86) p=0.009 
Meeus et al 20108 GBA 75 (PDD) + 99 (DLB): 
626 
“Mutant alleles” 3.01 (1.25-7.20)§ p=0.010 (LBD vs CTL) 
Seto-Salvia et al 201160 MAPT 41(LBD):374 H1 haplotype 2.69 (1.47-4.95) PDD: p=0.001 
Seto-Salvia et al 201160 MAPT 41(LBD):374 rs1467967  
 
0.54 (0.34-0.85) p=0.007‡ 
Guella et al 201619 SNCA 198:971 rs10018362 1.77 (1.28-2.45) p<0.002 
Guella et al 201619  198:971 rs7689942 2.10 (1.39-3.17) p<0.002 
Gatt et al 201374 TFAM 63:1410 rs2306604 2.09 (1.13-3.89) p=0.024 (AA genotype vs 
AG and GG) 
Shibata et al 201279 UCHL1  39:137 rs4861387  1.20 (0.58-2.50)§ p=0.03 
CTL: controls (CTL); PDND: Parkinson’s disease patients without dementia; †: p value has not been reported; ‡:  decreased frequency 






Figure-1: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow chart. 
Figure-2: Meta-analysis of studies that have investigated the genetic association between 
APOE-ε4 and dementia with Lewy bodies.  
Figure-3: Meta-analysis of studies that have investigated the genetic association between 
APOE-ε4 and Parkinson’s disease dementia. 
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